title: [Consideration of immune checkpoint inhibitors in cancer therapy].
abstract: Immune checkpoint inhibitor targets T-cell regulatory pathways by blocking negative signal to enhance antitumor immune response, and led to anti-tumor effect. This therapy has shown a durable clinical response which can lead part of cancer patients a long survival time. With lessons learned from advanced melanoma, I propose some questions and try to discuss some of them.
authors.affiliation: Clinical Development, Celgene Pharmaceutical (Shanghai) Co. Ltd, Shanghai 200020, China.
authors.forename: Y Y
authors.initials: YY
authors.lastname: Xu
mesh_terms: D059447:Cell Cycle Checkpoints / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects*